Navigation Links
ACL Reconstruction With Cadaver Tissue Risky in Younger Patients
Date:7/10/2008

Failure rate after surgery as high as 24% in middle-age patients, study shows

THURSDAY, July 9 (HealthDay News) -- Using replacement ligaments from cadavers for reconstruction of the anterior cruciate ligament (ACL) may have a failure rate as high as 24 percent in active patients under the age of 40.

The finding, from researchers at the Mississippi Sports Medicine and Orthopaedic Center, which were to be presented Thursday at the American Orthopaedic Society for Sports Medicine annual meeting, in Orlando, Fla., raises the question as to whether other alternatives would be better for younger ACL patients.

An estimated 800,000 ACL tears occur each year in the United States, with the number of ACL replacement surgeries correspondingly high.

Golf legend Tiger Woods may be the most recent well-known casualty. He recently announced that he would be undergoing ACL surgery this year, requiring him to sit out the rest of the 2008 season.

"The ACL is one of the ligaments in the center part of the knee that stops the shin bone from sliding forward," explained Dr. Derek K. Lichota, an assistant professor of surgery at Texas A & M Health Science Center College of Medicine and a sports medicine physician at Scott & White. "When you rupture it, the majority of patients' knees become unstable so, routinely, especially for young, active people, we recommend reconstruction."

The choices for reconstruction include a ligament from the patellar-tendon bone, the hamstring tendons or a ligament from a cadaver.

For this study, 64 patients aged 40 or older who had undergone ACL reconstruction with a replacement ligament from a cadaver were followed for at least two years.

Almost one-quarter (23.4 percent) of the reconstructions failed, meaning the patient had to undergo a second reconstruction because of additional injury, graft failure or low scores on a test of function.

The failure rate in an older group was only 2.4 percent.

While the findings may raise some red flags, a number of questions go unanswered, Lichota said.

"They don't tell us if the patients were braced postoperatively," he said, or when the second rupture occurred or the failure rates in specific subgroups of patients.

Also, the researchers did not describe the particular technique used for each replacement. "My concern is that we may be comparing apples to oranges," said Dr. William Levine, chief of sports medicine at NewYork-Presbyterian Hospital/Columbia in New York City.

More information

Visit the U.S. National Library of Medicine for more on ACL reconstruction.



SOURCES: Derek K. Lichota, M.D., assistant professor, surgery, Texas A&M Health Science Center College of Medicine, and sports medicine physician, Scott & White; William Levine, M.D., chief, sports medicine, NewYork-Presbyterian Hospital/Columbia, New York City; July 10, 2008, presentation, American Orthopaedic Society for Sports Medicine, annual meeting, Orlando, Fla.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Reconstruction surgery rarely discussed with breast cancer patients
2. Most breast cancer surgeons dont talk to patients about reconstruction options, U-M study finds
3. Breast Cancer Surgeons Dont Discuss Reconstruction Options
4. Implants Double Infection Risk After Breast Reconstruction
5. Smith & Nephew Orthopaedic Reconstruction Global Management Team Announced
6. Body identification by facial reconstruction will cost less time and money
7. Lack of patient-provider discussion contributes to disparities in use of breast reconstruction
8. Doctor-Patient Talks Affect Use of Breast Reconstruction Surgery
9. Breast Reconstruction Advances Fix Distortions Left by Lumpectomy
10. Breast reconstruction advances fix distortions left by lumpectomy
11. 98 percent of elective mastectomy patients would have reconstruction again, says ASPS study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ACL Reconstruction With Cadaver Tissue Risky in Younger Patients
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice ... on I learned that medicine is about more than making diagnoses and prescribing medicine,” ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the Phase ... an anti-P-selectin antibody, reduced the median annual rate of ... placebo (1.63 vs 2.98, p=0.010) in patients with or ... the data are being featured in the official press ... Hematology (ASH) Annual Meeting and presented during the Plenary ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: